{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:24:27Z","timestamp":1754144667171,"version":"3.41.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Science Center","award":["2015\/19\/B\/NZ5\/02229"],"award-info":[{"award-number":["2015\/19\/B\/NZ5\/02229"]}]},{"name":"Medical University of \u0141\u00f3d\u017a","award":["503\/1-090-01\/503-011-001","502-03\/1-090-01\/502-14-257"],"award-info":[{"award-number":["503\/1-090-01\/503-011-001","502-03\/1-090-01\/502-14-257"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.pharep.2016.05.011","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T23:00:34Z","timestamp":1468796434000},"page":"1002-1007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Everolimus treatment among patients with tuberous sclerosis affects serum lipid profile"],"prefix":"10.1007","volume":"68","author":[{"given":"Joanna","family":"Treli\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Dachowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kotulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergiusz","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"M\u0142ynarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"2","key":"10.1016\/j.pharep.2016.05.011_bib0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1\u2013TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.pharep.2016.05.011_bib0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pediatrneurol.2012.02.015","article-title":"Emerging treatments in the managements of tuberous sclerosis complex","volume":"46","author":"Kohrman","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"4","key":"10.1016\/j.pharep.2016.05.011_bib0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cmet.2013.08.002","article-title":"A central role for mTOR in lipid homeostasis","volume":"18","author":"Lamming","year":"2013","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.pharep.2016.05.011_bib0020","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/db09-1602","article-title":"Mammalian target of rapamycin complex 1 supresses lipolysis: stimulates lipogenesis and promotes fat storage","volume":"59","author":"Chakrabarti","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.pharep.2016.05.011_bib0025","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/petr.12007","article-title":"Lipid metabolism and oxydative stress in children after liver transplantation treated with sirolimus","volume":"16","author":"Jankowska","year":"2012","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10.1016\/j.pharep.2016.05.011_bib0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with use of mTOR inhibitors for cancer therapy","volume":"40","author":"Sivendran","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pharep.2016.05.011_bib0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1); a multicenter, randomized, placebo-controled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2016.05.011_bib0040","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomiolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicenter, randomized, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pharep.2016.05.011_bib0045","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11745-010-3488-y","article-title":"mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes","volume":"45","author":"Soliman","year":"2010","journal-title":"Lipids"},{"issue":"6","key":"10.1016\/j.pharep.2016.05.011_bib0050","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and imparing lipid deposition in adipose tissue","volume":"59","author":"Houde","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.pharep.2016.05.011_bib0055","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous Sclerosis Complex Consensus Conference: revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"10.1016\/j.pharep.2016.05.011_bib0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.pharep.2016.05.011_bib0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchromb.2013.03.014","article-title":"Two rapid ultra performance liquid chromatography\/tandem mass spectrometry (UPLC\/MS\/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay","volume":"928","author":"Borowiec","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.pharep.2016.05.011_bib0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2265.2011.04052.x","article-title":"HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults","volume":"75","author":"Fendler","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.pharep.2016.05.011_bib0075","first-page":"274","article-title":"A review of guidelines for dyslipidemia in children and adolescents","volume":"11","author":"Peterson","year":"2012","journal-title":"WMJ"},{"issue":"136","key":"10.1016\/j.pharep.2016.05.011_bib0080","first-page":"264","article-title":"Body mass index in the school age children and youth from the city of Lodz","volume":"23","author":"Nawarycz","year":"2007","journal-title":"Pol Merkur Lekarski"},{"issue":"6","key":"10.1016\/j.pharep.2016.05.011_bib0085","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4161\/cc.10.6.14930","article-title":"The integral role of mTOR in lipid metabolism","volume":"10","author":"Soliman","year":"2011","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.pharep.2016.05.011_bib0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.trre.2007.09.003","article-title":"Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors","volume":"22","author":"Cruzado","year":"2008","journal-title":"Transplant Rev"},{"issue":"12","key":"10.1016\/j.pharep.2016.05.011_bib0095","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1113\/expphysiol.2013.074930","article-title":"Modulation of food intake by mTOR signaling in the dorsal motor nucleus of the vagus in male rats: focus on ghrelin and nesfatin-1","volume":"98","author":"Zhang","year":"2013","journal-title":"Exp Physiol"},{"issue":"4","key":"10.1016\/j.pharep.2016.05.011_bib0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","article-title":"Complications of mTOR inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening","volume":"26","author":"Trelinska","year":"2015","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.pharep.2016.05.011_bib0105","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/pbc.25368","article-title":"Factors affecting response to everolimus therapy for subependymal giant cel astrocytomas associated with tuberous sclerosis","volume":"62","author":"Trelinska","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.pharep.2016.05.011_bib0110","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.tp.0000286095.55685.e9","article-title":"Sirolimus modifies cholesterol homeostasis in hepatic cells; a potential molecular mechanism for sirolimus-associated dyslipidemia","volume":"84","author":"Ma","year":"2007","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.pharep.2016.05.011_bib0115","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1172\/JCI61919","article-title":"Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice","volume":"122","author":"Ai","year":"2012","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.pharep.2016.05.011_bib0120","first-page":"1029","article-title":"Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice","volume":"119","author":"Han","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharep.2016.05.011_bib0125","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1476-5381.2008.00102.x","article-title":"Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels","volume":"156","author":"Chen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2016.05.011_bib0130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/jpet.108.144147","article-title":"Everolimus inhibits monocyte\/macrophage migration in vitro and their accumulation in carotoid lesions of cholesterol-fed rabbits","volume":"328","author":"Baetta","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2016.05.011_bib0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-\/- mice despite severe hypercholesterolemia","volume":"198","author":"Mueller","year":"2008","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pharep.2016.05.011_bib0140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Tranplant Rev"},{"issue":"23","key":"10.1016\/j.pharep.2016.05.011_bib0145","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.pharep.2016.05.011_bib0150","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.pharep.2016.01.005","article-title":"Management of side effectc of mTOR inhibitors in tuberous sclerosis patients","volume":"68","author":"Sadowski","year":"2016","journal-title":"Pharmacol Rep"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016300512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016300512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:33Z","timestamp":1752611793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2016.05.011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1734114016300512"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2016.05.011","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus treatment among patients with tuberous sclerosis affects serum lipid profile","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2016.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Urban & Partner Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.","name":"copyright","label":"Copyright"}]}}